drug · small molecule
BRIVARACETAM
Marketedupdated 3mo agoby UCB SA🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 8 investigational indications.
indications
investigational
Epilepsy
targets
Synaptic vesicle glycoprotein 2A
all catalysts(6)
approval · 6
Nov 13, 2025
approval
BRIVARACETAM — FDA approval
BRIVARACETAM
→
Feb 19, 2026
approval
BRIVARACETAM — FDA approval
BRIVARACETAM
→
Feb 23, 2026
approval
BRIVARACETAM — FDA approval
BRIVARACETAM
→
Feb 23, 2026
approval
BRIVARACETAM — FDA approval
BRIVARACETAM
→
Feb 23, 2026
approval
BRIVARACETAM — FDA approval
BRIVARACETAM
→
Feb 23, 2026
approval
BRIVARACETAM — FDA approval
BRIVARACETAM
→
Trials studying BRIVARACETAM
- phase3A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
- phase3A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
- phase3A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
- phase3Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy
- phase3A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy
- phase3A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
- phase3A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
- —Compassionate Use Program With Brivaracetam for the Treatment of Patients With Epilepsy
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 9, 2030
~3.6 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (12)
- Apr 9, 2030formulationUS 107296533.6y
- Apr 9, 2030formulationUS 107296533.6y
- Apr 9, 2030formulationUS 107296533.6y
- Apr 9, 2030formulationUS 107296533.6y
- Apr 9, 2030formulationUS 107296533.6y
- Feb 21, 2026compositionUS 6911461
- Feb 21, 2026compositionUS 6911461
- Feb 21, 2026compositionUS 6911461
- Feb 21, 2026compositionUS 6911461
- Feb 21, 2026compositionUS 6911461
- Feb 21, 2026compositionUS 6911461
- Feb 21, 2026compositionUS 6911461
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 15m ago
Found something off?
comments(0)
5-min edit window · permanent after that